

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

GAU 1641-

In Re the Application of:) Group Art Unit: 1641
FRANK et al.) Examiner: Pham, M.
Serial No.: 09/196,447) RESPONSE TO 5
Filed: November 19, 1998	NOTICE TO COMPLY WIFH SEQUENCE RULES OF RECEIVED
Atty. File No.: 2618-13-3-1) 27 EVE
For: "FILARIID ANTI-P22U ANTIBODIES" (as amended)	CERTIFICATE OF MAILING I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAD SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE ASSISTANT COMMISSIONER FOR
Assistant Commissioner for Patents Washington, D.C. 20231	PATENTS, WASHINGTON, DC 20231 ON 3/14/60. SHERIDAN ROSS P.C. BY: SHERIDAN ROSS P.C.

Dear Sir:

This response is filed in response to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures having a mailing date of March 2, 2000.

The computer readable form of the Sequence Listing of the present, above-identified patent application is identical to the computer readable form of the Sequence Listing of the parent application, U.S. Patent Application Serial No. 08/460,428, filed June 2, 1995. Pursuant to 37 CFR § 1.821(e), Applicants request that the compliant computer readable form of the Sequence Listing that is already on file for U.S. Patent Application Serial No. 08/460,428 be used in lieu of filing a duplicate computer readable form of the Sequence Listing in the present application. The paper copy of the Sequence Listing in the present application is identical to the computer readable copy of the Sequence Listing filed for U.S. Patent Application Serial No. 08/460,428.

No fees are believed to be due in connection with this response, but in the event that fees are due, please debit Deposit Account No. 19-1970.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: <u>Malla Dullas - Tedretti</u>
Angela Dallas-Pedretti
Registration No. 42,460

1560 Broadway, Suite 1200

Denver, CO 80202-5141

(303) 863-9700

Date: March 14, 2000

AR 17 2020 C)
Application No.: 09/196 447

NOTICE TO COMPLET WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicants attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 20 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: Applicant should follow the format of the attached sample statement to request that the CRF filed in the parent application be used to create a CRF in this application.
Applicant Must Provide:
An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
An <u>initial</u> or substitute paper copy of the "Sequence Listing". An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
An initial or substitute paper copy of the "Sequence Listing" as well as an amondment discrete.
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216